The FDA has expanded its warning on Moderna's COVID-19 vaccine due to a rare heart side effect, particularly among young males. This follows after the FDA approved an updated warning for all mRNA COVID-19 vaccines. Moderna, a leading player in mRNA vaccines, has recently faced several financial setbacks, including the U.S. government cancelling a contract with the company to produce a bird flu vaccine, leading to more than $700 million in lost funding. This coincides with growing uncertainty around Moderna's RSV vaccine and the future of its stock.
Despite these challenges, Moderna's mRNA technology remains in demand as demonstrated by the robust performance of MRNA against broader market conditions. Various safety concerns and recent scrutiny around mRNA vaccines have not deterred Moderna from advancing its research. The company continues to develop its pandemic preparedness agenda with U.K. approval for commercial mRNA vaccine plant. Moderna recently submitted a upgraded version of its COVID vaccine for regulatory review.
Notably, FDA has also approved Moderna's next-generation COVID-19 vaccine for use in adults aged 65 and older, despite investor nervousness, suggesting promising future prospects.
Moderna MRNA News Analytics from Thu, 29 Aug 2024 07:00:00 GMT to Fri, 27 Jun 2025 15:12:00 GMT - Rating -3 - Innovation 2 - Information 5 - Rumor 1
